Sign in
Taking people in United StatesPhase 2

Remote lifestyle program for older adults with knee or hip osteoarthritis pain

Tests a remote lifestyle program for older adults with knee or hip osteoarthritis pain.

Key facts

Who runs it
Wake Forest University
Where
Winston-Salem, United StatesSee the site
Trial code
Registry title
A Mobile Intervention to Reduce Pain and Improve Health-III
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
14 Aug 2025
Expected to end
31 Aug 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MORPH
  • Measurement Only
Record updated
20 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults, aged 65 or more, with knee or hip osteoarthritis pain who are overweight or obese and not very active. It tests a 6-month remote program on activity, pain, weight and physical function.

Age
65 years or older
Sex
Women and men can join.
Disease stage
Knee or hip osteoarthritis, found with the Roux questionnaire. Body mass index of 30-45 kg/m2, or over 45 kg/m2 with the doctor's approval.
Earlier treatment
Must not be using a weight loss medication. Medicines for diabetes are allowed if weight is stable. No joint replacement or other bone surgery in the past 6 months.

Main reasons for not taking part

  • Living in a skilled nursing facility, rehab or assisted living
  • History of mild cognitive impairment or dementia, or a low score on the TICS-M memory survey
  • Untreated or unstable depression or anxiety (PHQ-9 above 15)
  • Joint replacement or other bone surgery planned in the next 18 months
  • Kidney failure needing dialysis, cancer needing current treatment, or severe heart disease

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Aged 65+ years
  • Body mass index of 30-45 kg/m2 or >45 kg/m2 with physician's approval
  • No loss or gain of more than 5% body mass in previous 6 months
  • Presence of knee or hip osteoarthritis as ascertained via the Roux questionnaire
  • Independently living
  • Low active (i.e., not participating in regular resistance training and/or >20 mins/day of aerobic exercise on more than 2 days/week in past 3 months as ascertained via a modified CHAMPS questionnaire)
  • Have no contraindication for safe and optimal participation in exercise based on EASY screening (pertaining to chest pain and discomfort during physical activity, dizziness or light headedness, or frequent falls and use of assistive devices)
  • Not currently using a weight loss medication (medications for diabetes management are permitted if weight stable)
  • Approved for participation by medical director
  • Willing to provide informed consent and agree to all study procedures and assessments

Who cannot take part

  • Hospitalization for psychiatric event within past year prior to screening
  • Currently using a weight loss medication (medications for diabetes management are permitted if weight stable)
  • Joint replacement or other orthopedic surgery in past 6 months
  • Joint replacement or other orthopedic surgery planned in next 18 months
  • History of pharmacologic treatment for a psychiatric disorder other than depression/anxiety within past year
  • History of mild cognitive impairment or dementia
  • Cognitive impairment (<32) on Modified Telephone Interview for Cognitive Status survey (TICS-M)
  • Hearing or visual impairment that would preclude use of the videoconferencing software
  • Severe arthritis or other musculoskeletal disorder that is a contraindication for safe walking
  • Have a diagnosis of uncontrolled hypertension; current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease other than asthma or COPD, any disease requiring oxygen use, neurological or hematological disease; cancer requiring current treatment, except non-melanoma skin cancers; kidney failure requiring dialysis; have a Katz ADL disability; or engage in heavy alcohol use >14 drinks/week
  • Reside in skilled nursing facility, rehab or assisted living environment
  • Current untreated and/or unstable clinical depression or anxiety (Patient Health Questionnaire (PHQ-9) >15)
  • Presently undergoing treatment for orthopedic fracture
  • Contraindication based on EASY screening (pertaining to chest pain and discomfort during physical activity, dizziness or light headedness, or frequent falls and use of assistive devices) without physician approval
  • Current participation in other research study with a prospective intervention
  • Unable/unwilling to commit to study protocol, including random assignment and use of technology tools
  • Unable/unwilling to attend three virtual testing appointments

Where in United States

  • Wake Forest UniversityWinston-Salem, United StatesContact: Deja DobsonTaking people

About the trial

What the trial wants to find out

The experience of chronic pain powerfully and negatively affects quality of life and functional independence in aging. Unfortunately, while as many as three in four older adults experience chronic pain, few have access to effective non-pharmacological pain management strategies. Participating in regular physical activity, avoiding sustained sitting, and maintaining a healthy weight are important and interrelated lifestyle inputs to chronic pain, and socially rich behavioral interventions informed by contemporary theories of behavior change appear important for engaging in activity and healthy eating in the long term. Our group has demonstrated in a series of Stage I trials that a group-mediated behavioral intervention combining dietary behavior change and a physical activity program focused on moving often throughout the day contributes to meaningful weight loss, and lasting weight maintenance, with pilot data suggesting this may contribute to improved pain, physical function, and health-related quality of life among older adults with chronic pain. As these were NIH Stage I trials, there are several important gaps to be addressed in the present trial: (1) both studies of chronic pain recruited small samples and were 12 weeks in duration, limiting our ability to establish efficacy and the durability of changes to activity, HRQOL, and pain outcomes; (2) participants included anyone with chronic pain, regardless of pain type, a likely contributor to heterogeneous pain intensity and interference findings; and (3) the investigators have yet to examine behavioral maintenance.

Read full original descriptionShow less

The overarching goal of the proposed Stage II "mobile intervention to reduce pain and improve health-III (MORPH-III)" is to establish the efficacy of the intervention for enhancing physical activity via steps (primary), and for reducing pain interference and body weight while enhancing physical function (secondary) among older adults with chronic knee or hip osteoarthritic (OA) pain. The investigators will recruit 200 older adults with knee or hip osteoarthritic pain to engage in a 6-month remotely delivered intervention comprising weekly group or individual intervention meetings plus brief individual goal-setting coaching calls. This will be followed by a 12-month no-contact maintenance period, where participants will attempt to sustain behavioral goals on their own.

The Specific Aims are:

Specific Aim 1: To examine the impact of MORPH on ActivPAL-assessed daily steps relative to an enhanced usual care control. Hypotheses: MORPH will significantly increase steps relative to control at month 6.

Specific Aim 2: To examine the impact of MORPH on pain interference, change in body weight, and physical function relative to the enhanced usual care control. Hypotheses: MORPH will result in significant reductions in pain interference and body weight and improvement in physical function relative to control at month 6.

Exploratory Aims: Aim 1: To investigate the impact of the MORPH intervention on steps, weight change, pain interference, and physical function at month 18. Aim 2: If the MORPH intervention results in reduced pain interference at 6 and/or 18 months, the investigators will examine the extent to which 6-month change in steps, weight, pain self-efficacy, and catastrophizing mediate change in interference at 6 and/or 18 months.

The 2 groups in the trial

  • MORPHTreatment being tested

    MORPH participants will attend one weekly group-mediated session alongside a group of their peers plus individual coaching calls. Participants will aim to increase daily steps by moving often throughout the day, using an activity monitor and mHealth app to view feedback and set goals. Participants will also aim to weight via healthy eating while reducing daily calories by \~400kcal/day below weight maintenance needs to achieve approximately 6% weight loss in 6 months and 10% over 18 months.

  • Measurement OnlyExisting treatment, for comparison

    Measurement-only participants will receive an activity monitor and wireless weight scale to account for the effect of these self-monitoring technologies and activity behavior.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Mobile Intervention to Reduce Pain and Improve Health-III
Plain-language title
Remote lifestyle program for older adults with knee or hip osteoarthritis painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 February 2026